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Abstract 
Objectives  
Palliative self-expandable metallic stent (SEMS) insertion is common in patients not suitable 
for resection of oesophago-gastric (OG) cancer.  Factors which may determine survival 
however are not clear.  The present study examined the relationship between tumour and host 
factors, including the systemic inflammatory response, and survival of patients undergoing 
palliative SEMS insertion. 
Methods 
Patients with a diagnosis of OG cancer who were considered suitable for palliative SEMS 
only without systemic therapy were identified.  Patient characteristics including Eastern 
Cooperative Oncology Group performance status, radiological stage and modified Glasgow 
Prognostic Score (mGPS: 0-CRP≤10mg/L, 1-CRP>10mg/L, 2-CRP>10mg/L, 
albumin<35g/L) were recorded prospectively.  The relationship between such characteristics 
and three-month survival was examined. 
Results 
203 patients were included in the final analysis.  All patients died during follow-up, with 
median survival from diagnosis 75 days (interquartile range 47-157). 78% of patients were 
systemically inflamed (mGPS>1).  On multivariate analysis, only poor performance status 
(HR 1.23, P=0.025), metastatic disease (HR 2.27, P<0.001) and mGPS (HR 1.25, P=0.021) 
were associated with shorter survival.  The combination of performance status and mGPS 
stratified three-month survival of patients without metastatic disease from 88% to 20% 
(P<0.001) and patients with metastases from 43% to 6% (P=0.059).  Similar results were 
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observed when analysis was restricted to patients with oesophageal and junctional cancer 
(M0: 83% to 20%, P=0.008; M1: 33% to 8%, P=0.082). 
 
Conclusion 
Performance status, metastatic disease and mGPS are independent predictors of survival in 
patients with OG cancer undergoing palliative SEMS insertion.  These routinely available 
markers provide a rational system on which to base decisions regarding prognosis and 
treatment. 
 
Keywords: Gastrointestinal (upper); prognosis; dysphagia. Self-expandable metallic 
stent; systemic inflammation 
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INTRODUCTION 
Several modalities have now been established for the palliation of patients with advanced or 
inoperable oesophago-gastric (OG) cancer.  Although maximal survival benefit can be 
obtained from the use of systemic palliative chemotherapy,[1] patient frailty and comorbidity 
may preclude its use.  Furthermore, significant symptoms, such as dysphagia and vomiting 
secondary to gastric outlet obstruction, may necessitate more urgent and direct palliation.  
Insertion of a self-expandable metallic stent (SEMS) is a feasible option for palliation, and is 
effective in the rapid alleviation of significant dysphagia, a distressing symptom.[1-3]  Given 
that the procedure may be performed with only a brief hospital stay, SEMS insertion is a 
useful adjunct in the management of a patient group with limited life expectancy.[1, 4, 5] 
Stent insertion may be effective in the short term, however may be associated with a high risk 
of morbidity and re-intervention.[6]  Other modalities, such as brachytherapy may have 
similar long-term efficacy with less risk of morbidity but with a slower resolution of 
dysphagia.[1, 7, 8]  Although of limited benefit in patients with extremely poor prognosis, 
such treatments may be more appropriate for patients with a reasonable life expectancy.[1, 9]  
Identifying tumour and host characteristics which may guide prognosis in this patient group 
would be of use in differentiating between such different treatment options.  
Previous studies have reported the presence of metastatic disease and poor performance status 
as predictors of poor survival and therefore indications for urgent SEMS insertion.[9, 10] 
Similarly, markers of poor nutrition are common in patients with OG cancer,[11] and predict 
short-term survival; indeed, need for intensive nutritional therapy, low BMI and low serum 
albumin concentrations have all previously been associated with mortality at 30 days.[10, 12] 
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However, albumin is a negative acute phase reactant, and declining serum concentrations 
may be more reflective of the magnitude of the systemic inflammatory response rather than 
nutritional status.[13]  Systemic inflammation is an important determinant of disease 
progression and survival in patients with cancer,[14] and various prognostic scores 
incorporating routine measures of the systemic inflammatory response have been proposed 
for use in advanced cancer.[15, 16]  One such score, the modified Glasgow Prognostic Score 
(mGPS), is based on the combination of serum C-reactive protein (CRP) and albumin 
concentrations and has been shown to hold prognostic value not only across several solid 
organ cancers, but also across patients undergoing treatment with both curative and palliative 
intent.[17, 18]   
As such, the systemic inflammatory response, and the mGPS appears a rational and easily 
measurable characteristic on which to base a prognostic scoring system for patients with 
advanced OG cancer.  Therefore, the aim of the present study was to examine the prognostic 
value of the mGPS in addition to other host and tumour characteristics in patients undergoing 
palliative SEMS insertion for OG cancer.
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PATIENTS AND METHODS 
Patients were identified from a prospectively maintained database of OG cancers discussed at 
the regional West of Scotland Upper Gastrointestinal Cancer multidisciplinary meeting 
(MDM).  For the purposes of the present study, patients with incident, biopsy-proven 
adenocarcinoma and squamous carcinoma arising from the upper third of oesophagus to 
pylorus, and who were considered suitable for palliative SEMS insertion only without 
systemic palliative chemotherapy between January 2009 and December 2013 were included.  
The decision to proceed with SEMS insertion only was based on several factors which would 
preclude curative or systemic palliative therapy, including patient symptoms and preferences, 
age, comorbidities and performance status, and the presence of locally advanced or metastatic 
disease on staging thoracoabdominal computed tomography (CT) staging.  No specific 
criteria or thresholds for performance status or co-morbidities were utilised in determining 
eligibility for SEMS insertion; rather, the decision was made on the basis of each individual 
patient.  No formal dysphagia scoring system was used either prior to or following SEMS 
insertion.  In addition, formal assessment of nutritional status or requirements was not 
routinely performed or recorded prospectively. 
Clinical characteristics, including tumour site, were recorded prospectively at time of 
diagnosis.  For the purposes of analysis, tumours arising from the OG junction were 
considered oesophageal in origin.  Performance status was assessed using Eastern 
Cooperative Oncology Group grade (ECOG), ranging from grade 0 (fully active; able to carry 
on all pre-disease performance without restriction) to grade 4 (completely disabled; cannot 
carry on any self-care; totally confined to bed or chair).[19]  Radiological TNM stage was 
determined by CT staging, with metastatic disease considered as evidence of solid organ or 
peritoneal metastases. 
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Serum C-reactive protein (CRP) and albumin concentrations were measured at time of 
diagnosis.  The mGPS was calculated as follows: 0 - CRP≤10mg/L, 1 - CRP>10mg/L, and 2 - 
CRP>10mg/L and albumin<35g/L. 
Overall survival was obtained from electronic hospital administration records and measured 
in days as survival from diagnosis.  Follow-up ended at the death of the last patient. Need for 
repeat endoscopic intervention (manipulation or dilatation of stent, insertion of a further stent, 
laser ablation or clearance of an obstructing bolus), and complication rate (blockage or 
migration of stent, perforation) following initial SEMS insertion was identified 
retrospectively from electronic case notes.  NHS Greater Glasgow & Clyde Clinical 
Governance and West of Scotland Upper Gastrointestinal Cancer Managed Clinical Network 
provided approval for this study. 
Statistical analysis 
The relationship between clinicopathological characteristics and survival was examined using 
univariate Cox proportional hazards regression to calculate hazard ratios (HR) and 95% 
confidence intervals (95%CI).  Variables with a P-value<0.1 on univariate analysis were 
entered into a multivariate model using a backwards conditional method.  Patients with data 
missing for variables were not excluded from analysis.  The relationship between variables 
independently associated with survival and percentage survival rate at three months (standard 
error) was subsequently examined using Kaplan-Meier curves and log rank survival analysis.  
A P-value≤0.05 was considered statistically significant.  All statistical analysis was 
performed using SPSS version 22.0 for Mac (IBM SPSS, Armonk, NY, USA).
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RESULTS 
219 patients were considered for palliative stent insertion for OG cancer.  Sixteen patients 
were subsequently excluded: serum CRP at diagnosis was missing for 11 patients, two 
received systemic chemotherapy, and date of stent insertion and date of death were not 
available for two patients and one patient respectively.  Of the remaining 203 patients 
included in the study, data were missing on T stage, N stage and M stage for 33, 14 and 9 
patients respectively; 9 patients did not undergo staging CT due to frailty and MDM 
agreement that radiological staging would not alter management.  Of the remaining patients, 
radiological assessment of the primary tumour or presence of regional lymph node metastases 
was not recorded at the time of MDM.  Data on repeat endoscopic intervention and 
complication rates were missing for 15 patients. 
The clinicopathological characteristics of the 203 included patients are displayed in Table 1.  
Eighty-seven percent of patients were 65 or older at time of diagnosis, 55% were male and 
40% of patients were performance status 0-1.  Eighty percent of patients were diagnosed with 
an oesophageal or junctional cancer, with metastatic disease evident in 40% of cases.  Median 
CRP was 29mg/L (interquartile range 13-74), and median albumin was 31g/L (26-35).  An 
elevated CRP (>10mg/L) was present in 78% of patients, and a low albumin (<35g/L) was 
identified in 75% of patients.  Serum CRP and albumin concentrations were inversely 
correlated (Spearman’s rho correlation coefficient: r=-0.484, P<0.001), with a low serum 
albumin observed in 82% of patients with an elevated CRP (n=129) compared to only 51% of 
patients with a low CRP (n=23, Chi-square analysis for linear trend P<0.001).  Twenty-two 
percent of patients had mGPS=0, whereas 15% and 64% of patients had mGPS=1 and 2 
respectively. 
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Table 1. Clinicopathological characteristics of patients undergoing palliative insertion 
of self-expandable metallic stent for oesophago-gastric cancer 
 
Clinicopathological characteristics N (%) 
Age (<65/65-74/75) 26 (13)/ 39 (19)/ 138 (68) 
Sex (Male/ female) 112 (55)/ 91 (45) 
Performance Status (0-1/ 2/ 3/ 4) 81 (40)/ 61 (30)/ 54 (27)/ 7 (3) 
Tumour site (Oesophageal-junctional/ gastric) 163 (80)/ 40 (20) 
T stage (1/ 2/ 3/ 4) (170) 12 (7)/ 35 (21)/ 77 (45)/ 46 (27) 
N stage (0/ 1/ 2/ 3) (189) 54 (29)/ 87 (46)/ 43 (21)/ 5 (3) 
Node positive (No/ yes) (189) 54 (29)/ 135 (71) 
M stage (0/ 1) (194) 116 (60)/ 78 (40) 
mGPS (0/ 1/ 2)  45 (22)/ 29 (15)/ 129 (64) 
Median time to stent (days) 19 (10-30)  
Median Survival from diagnosis (days) 75 (47-157) 
Median Survival from stent (days) 53 (27-129) 
 
(n) given when data incomplete. Continuous variables displayed as median (interquartile 
range).  CRP – C-reactive protein, mGPS – modified Glasgow Prognostic Score 
 
All patients died during follow-up, with a median survival from diagnosis of 75 days.  The 
median time from diagnosis to stent insertion was 19 days and median survival following 
stent insertion was 53 days.  Three patients subsequently received palliative radiotherapy.  
Thirty-seven patients (19%) underwent repeat endoscopic intervention; 28 patients underwent 
one further intervention, four patients underwent two, whereas three patients and one patient 
underwent five and seven repeat interventions respectively.  Thirty-two patients (16%) had at 
least one complication, with 8 stent perforations identified. 
The relationship between clinicopathological characteristics and survival following diagnosis 
is displayed in Table 2.  On univariate survival analysis, poor performance status (HR 1.15, 
95%CI 0.98-1.35, P=0.079), advancing T stage (HR 1.23, 95%CI 1.03-1.47, P=0.026), 
lymph node involvement (HR 1.33, 95%CI 0.96-1.83, P=0.085), positive M stage (HR 2.13, 
95%CI 1.58-2.88, P<0.001), and an elevated mGPS (HR 1.32, 95%CI 1.12-1.55, P=0.001) 
were associated with shorter survival, whereas age, sex, tumour site, and N stage were not.  
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On multivariate analysis, only poor performance status (HR 1.23, 95%CI 1.03-1.48, 
P=0.025), positive M stage (HR 2.27, 95%CI 1.61-3.19, P<0.001) and an elevated mGPS 
(HR 1.25, 95%CI 1.03-1.49, P=0.021) were independently associated with shorter survival.   
Table 2. Relationship between serum albumin and C-reactive protein concentrations, 
clinicopathological characteristics and survival following diagnosis of patients with 
oesophago-gastric cancer undergoing palliative insertion of self-expandable metallic 
stent 
 
Clinicopathological characteristics  Univariate P  Multivariate P 
Age <65 
65-74 
75 
 0.91 (0.75-1.10) 0.308  - - 
Sex Male 
Female 
 0.97 (0.84-1.29) 0.846  - - 
Performance Status 0-1 
2 
3 
4 
 1.15 (0.98-1.35) 0.079  1.23 (1.03-1.48) 0.025 
Tumour site OG/J 
Gastric 
 0.86 (0.60-1.22) 0.392  - - 
T stage 1 
2 
3 
4 
 1.23 (1.03-1.47) 0.026  - 0.349 
N stage 0 
1 
2 
3 
 1.16 (0.97-1.38) 0.103  - - 
Node positive No 
Yes 
 1.33 (0.96-1.83) 0.085  - 0.438 
M stage 0 
1 
 2.13 (1.58-2.88) <0.001  2.27 (1.61-3.19) <0.001 
mGPS 0 
1 
2 
 1.32 (1.12-1.55) 0.001  1.24 (1.03-1.49) 0.021 
CRP – C-reactive protein, mGPS – modified Glasgow Prognostic Score 
The relationship between performance status, M stage and mGPS and survival at three 
months following diagnosis was subsequently examined in patients with oesophago-gastric 
cancer (n=194).  For the purposes of further analysis, mGPS was categorised as mGPS 0 
(n=45) and mGPS 1-2 (n=158).  Performance status stratified three-month survival from 48% 
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to 29% (P=0.235).  M stage stratified three-month survival from 57% to 21% (P<0.001), 
whereas the mGPS stratified survival from 69% to 34% (P<0.001) (Figure 1).   
When patients without metastases were considered (Table 3), performance status stratified 
survival from 62% to 33% (P=0.164), and mGPS stratified survival from 84% to 47% 
(P=0.003).  The combination of performance status and mGPS stratified three-month survival 
from 88% (M0, ECOG 0/1, mGPS 0, n=16) to 20% (M0, ECOG 4, mGPS 1-2, n=5) 
(P<0.001). When patients with metastases were considered, performance status stratified 
survival from 31% to 6% (P<0.001), whereas mGPS stratified survival from 38% to 17% 
(P=0.048).  The combination of performance status and mGPS stratified three-month survival 
from 43% (M1, ECOG 0/1, mGPS 0, n=7) to 6% (M1, ECOG 4, mGPS 1-2, n=16) 
(P=0.059). 
Table 3. The relationship between metastatic disease status, performance status and 
modified Glasgow Prognostic Score and survival rate at three months in patients 
undergoing palliative self-expandable metallic stent insertion for oesophago-gastric 
cancer 
 
M status Performance status mGPS 0 (n=31) mGPS 1-2 (n=85) mGPS 0-2 (n=116) 
M0 ECOG 0/1 (n=45) 88% (8) (n=16) 48% (9) (n=29) 62% (7) 
ECOG 2 (n=33) 100% (0) (n=7) 54% (10) (n=26) 64% (8) 
ECOG 3 (n=32) 57% (19) (n=7) 44% (10) (n=25) 47% (9) 
ECOG 4 (n=6) (n=1) 20% (18) (n=5) 33% (19) 
ECOG 0-4 (n=116) 84% (7) 47% (5) 57% (5) 
M1  mGPS 0 (n=13) mGPS 1-2 (n=65) mGPS 0-2 
(n=78) 
 ECOG 0/1 (n=36) 43% (19) (n=7) 28% (8) (n=29) 31% (8) 
 ECOG 2 (n=25) 33% (19) (n=6) 11% (7) (n=19) 16% (7) 
 ECOG 3 (n=16) (n=0) 6% (6) (n=16) 6% (6) 
 ECOG 4 (n=1) (n=0) (n=1) - 
 ECOG 0-4 (n=78) 38% (13) 17% (5) 21% (5) 
 
Survival displayed as percentage survival (standard error). Survival not calculated if n<5 
 
Analysis was subsequently performed in patients undergoing palliative SEMS insertion for 
oesophageal and junctional cancer only (Table 4, n=154).  The combination of performance 
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status and mGPS stratified three-month survival of patients without metastases from 83% 
(M0, ECOG 0/1, mGPS 0, n=12) to 20% (M0, ECOG 4, mGPS 1-2, n=5) (P=0.008), and 
stratified three-month survival of patients with metastases from 33% (M1, ECOG 0/1, mGPS 
0. n=6) to 8% (M1, ECOG 3, mGPS 1-2, n=13) (P=0.082). 
Table 4. The relationship between metastatic disease status, performance status and 
modified Glasgow Prognostic Score and survival rate at three months in patients 
undergoing palliative self-expandable metallic stent insertion for oesophageal cancer  
 
M 
status 
Performance 
status 
mGPS 0  
(n=24) 
mGPS 1-2  
(n=70) 
mGPS 0-2 
(n=94) 
M0 ECOG 0/1 (n=37) 83% (11) (n=12) 52% (10) (n=25) 62% (8) 
ECOG 2 (n=25) 100% (0) (n=6) 58% (11) (n=19) 68% (9) 
ECOG 3 (n=26) 60% (2) (n=5) 48% (11) (n=21) 50% (10) 
ECOG 4 (n=6) (n=1) 20% (18) (n=5) 33% (19) 
ECOG 0-4 (n=94) 83% (8) 50% (6) 59% (5) 
M1  mGPS 0  
(n=11) 
mGPS 1-2  
(n=49) 
mGPS 0-2 
(n=60) 
 ECOG 0/1 (n=28) 33% (19) (n=6) 32% (10) (n=22) 32% (9) 
 ECOG 2 (n=18) 40% (2) (n=5) 8% (7) (n=13) 17% (9) 
 ECOG 3 (n=13) (n=0) 8% (7) (n=13) 8% (7) 
 ECOG 4 (n=1) (n=0) (n=1) - 
 ECOG 0-4 (n=60) 36% (15) 18% (6) 22% (5) 
 
Includes patients with gastro-oesohageal junctional cancer. Survival displayed as percentage 
survival (standard error). Survival not calculated if n<5 
 
The relationship between performance status, M stage, mGPS and need for repeat endoscopic 
intervention and complication rates was examined. (Table 5). Thirty-five patients required re-
intervention, predominantly for endoscopic laser ablation (n=8), re-stenting (n=9) or 
clearance of a food bolus (n=5), with the remaining patients requiring stent repositioning, 
dilatation or NJ tube insertion.  Thirty patients developed a SEMS-related complication, with 
blocked stent (n=11), stent migration (n=8) and perforation (n=7) the most common.  Neither 
performance status nor M stage were associated with rates of reintervention or complications 
following SEMS insertion.  Patients with mGPS 0-1 were more likely to undergo repeat 
intervention compared to those with mGPS 2 (P=0.007).  Furthermore, patients with mGPS 2 
were less likely to experience a SEMS-related complication (P=0.041). 
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Table 5. The relationship between performance status, metastatic disease and modified 
Glasgow Prognostic Score and repeat endoscopic intervention and complication rates in 
patients undergoing palliative self-expandable metallic stent insertion for oesophageal 
cancer  
 
 Re-intervention Complications 
 No Yes P No Yes P 
Performance status 
0-1 
2 
3 
4 
 
65 (82) 
48 (81) 
44 (81) 
5 (71) 
 
14 (18) 
11 (19) 
10 (19) 
2 (29) 
0.679  
64 (81) 
50 (85) 
47 (87) 
6 (86) 
 
15 (19) 
9 (15) 
7 (13) 
1 (14) 
0.364 
M stage 
0 
1 
 
92 (79) 
64 (86) 
 
25 (21) 
10 (14) 
0.173  
98 (82) 
65 (88) 
 
21 (18) 
9 (12) 
0.286 
mGPS 
0 
1 
2 
 
29 (71) 
19 (70) 
107 (88) 
 
12 (29) 
8 (30) 
15 (12) 
0.007  
32 (78) 
20 (74) 
109 (89) 
 
9 (22) 
7 (26) 
13 (11) 
0.041 
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DISCUSSION 
In the present study, poor performance status, metastatic disease and the presence of elevated 
systemic inflammatory responses as measured by mGPS were independently associated with 
survival of patients undergoing palliative SEMS insertion for OG cancer.  The combination 
of these routinely available characteristics provides a framework for determining prognosis 
and the rational selection of treatment modalities in a patient group with limited treatment 
options and survival.  
The present results are consistent with previous work by Steyerberg and colleagues, whereby 
assessment of performance status and metastatic disease burden could identify patients likely 
to benefit from brachytherapy rather than SEMS insertion.[9]  Such characteristics are 
routinely collected at time of diagnosis and staging, and given their well-established value, 
provide a logical backbone on which to base prognosis. 
The mGPS was independently associated with survival, and when compared to performance 
status, had greater fidelity in stratifying survival.  This likely reflects the objective nature of 
serum markers of inflammation (i.e. high or low), compared to the more subjective nature of 
assessment of a patient’s physical activity and performance status.[20]  However, in keeping 
with previous work,[18] the combination of both measures provided complimentary 
prognostic information, particularly when further stratified by M stage; indeed, it was 
possible to identify patients with oesophageal cancer and a relatively good prognosis with 
expected survival rate at three months of 83% and who may benefit from consideration of 
other modalities rather than SEMS insertion.[1, 9]  Conversely, it was also possible to 
identify patients with a dismal prognosis and three-months survival of around 8%; this groups 
would be more likely benefit from immediate palliation by SEMS insertion as well as 
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accelerated referral to palliative care services.  The results of the present study however must 
be interpreted with caution given the small numbers of patients in each subgroup, and remain 
to be confirmed in the context of a larger validation study. 
Of interest, patients without elevated systemic inflammatory markers at time of diagnosis 
were more likely to require repeat endoscopic intervention and were more likely to 
experience complications following SEMS insertion.  Rather than being causative, this likely 
reflects the superior survival of patients with mGPS 0 compared to those with mGPS 2; as 
patients survive longer, they will more likely require repeated interventions to maintain 
SEMS patency and adequate oral nutrition.  Indeed, consistent with previous work by 
Steyerberg,[9] the present results would suggest that SEMS insertion should be favoured for 
patients with extremely poor prognosis, whereas other modalities, such as temporary 
nasoenteral feeding and palliative radiotherapy or brachytherapy, should be considered in 
patients with relatively good predicted survival.  Further clinical trials predicated upon this 
premise are warranted.  
To our knowledge, only one previous study has examined the prognostic value of the 
systemic inflammatory response in patients undergoing palliative SEMS insertion for OG 
cancer.[21]  However, a significant proportion of patients were Human Immunodeficiency 
Virus (HIV) positive, and the study utilised a threshold CRP>150mg/L.  In the present study, 
only 16 patients (7%) had a CRP>150mg/L at diagnosis.  Given that the mGPS has been 
validated globally across a number of cancer-associated clinical scenarios,[17] the present 
results are more generalisable to a Western population. 
Previous work by Lecleire and colleagues identified declining serum albumin concentration 
as an independent predictor of 30-day mortality in patients undergoing SEMS insertion,[10] 
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and similarly other groups have reported hypoalbuminaemia as an adverse prognostic factor 
in a variety of clinical scenarios.[22, 23]  However, although these studies have assumed 
albumin as a marker of nutrition, hypoalbuminaemia is a late manifestation of malnutrition 
and alone poorly reflects nutritional status.[24, 25]  Rather the present results, whereby 
almost 80% of patients with a low albumin also had an elevated CRP, more accurately reflect 
our understanding of changes in serum albumin in patients with cancer, where it is more 
likely to reflect the systemic inflammatory response rather than nutritional status.[26] 
Indeed, previous studies have reported continuing nutritional decline and weight loss as an 
adverse prognostic factor following palliative SEMS insertion.[10, 12]  This is likely a 
manifestation of the cancer cachexia syndrome,[27] of which systemic inflammation is an 
integral step in patients with oesophageal cancer.[28, 29]  If such features were solely a 
marker of nutrition alone, it would be expected that nutritional status, including serum 
albumin concentrations, would increase even transiently following SEMS insertion and 
resolution of dysphagia.  To the contrary however, Lecleire et al. reported a continuing 
decline.[10]  Similarly, provision of intensive nutritional support or resolution of dysphagia 
did not result in improvement in survival or markers of nutrition in reported studies of 
patients undergoing SEMS insertion.[10, 12]  Taken together, these studies, along with the 
present results, suggest a pertinent role for the systemic inflammatory response in driving 
nutritional decline and cachexia in patients with advanced OG cancer. 
The present results suggest that management of nutrition and cancer cachexia would not only 
involve intensive nutritional support, but also the use of anti-inflammatory drugs.  A targeted 
role for such agents in improving nutritional status as well as alleviating symptoms of 
cachexia has been proposed.[29-31]  In keeping with this, a multi-modality approach 
incorporating non-steroidal anti-inflammatory drugs and nutritional support has been shown 
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to be feasible in patients with advanced cancer.[32]  The presently recruiting MENAC trial 
aims to investigate the effects of such an intervention on body composition and performance 
status in patients receiving palliative chemotherapy for advanced pancreatic and lung 
cancer.[33]  It would be of interest to examine such an approach in the context of the 
palliation of oesophago-gastric cancer; indeed, whether the assessment of systemic 
inflammatory profiles and performance status would not only guide prognosis but also allow 
for stratification of palliative therapy options remains of interest and warrants further study.   
The present study is limited by a lack of robust measures of nutritional status or body 
composition.[29]  Aside from ECOG performance status, no objective measurement of 
function or physical activity was performed.  Assessment of such measures at baseline and 
and their prognostic value relative to the systemic inflammatory response, as well their 
changes over time, would be of interest.  Furthermore, no formal dysphagia scoring system 
was applied to decide on appropriateness of SEMS insertion, therefore it cannot be 
determined if patients were similar with regards to symptom profile.  However, the decision 
to proceed to SEMS insertion in our institution is generally decided upon following MDT 
agreement. 
A strength of the present study is that this was a prospectively collected cohort of patients 
who were relatively uniform with respect to cancer treatment.  As such it provides a 
pragmatic overview of current clinical practice.  However, limitation of the study group to 
those considered unsuitable for systemic therapy limits the clinical relevance of the present 
results; only 23 patients fell into the good prognosis group with expected three-month 
survival rates over 88%.  Further study in patients receiving systemic palliative therapy 
would be of interest, and may allow for greater clinical impact in a larger patient cohort. 
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In summary, poor performance status, the presence of metastatic disease and the presence of 
an elevated systemic inflammatory response as measured by the mGPS, are independent 
predictors of poor survival in patients undergoing palliative SEMS insertion for OG cancer.  
These routinely available characteristics may aid in not only determining prognosis, but also 
in the rational selection of appropriate symptom-based treatment of dysphagia and nutrition. 
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Figure 1. Relationship between (a) performance status (P=0.235), (b) presence of metastatic 
disease (P<0.001), (c) modified Glasgow Prognostic Score (P<0.001) and survival following 
diagnosis of patients with oesophago-gastric cancer undergoing palliative self-expandable 
metallic stent insertion 
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